Tous Actualités
Suivre
Abonner Antisoma plc

Antisoma plc

Antisoma in-licenses telomerase inhibitor programme from Cancer Research Technology

London, UK (ots)

Antisoma plc, (LSE: ASM; Nasdaq Europe: ASOM)
the biopharmaceutical company specialising in novel anti-cancer
drugs, today announces that it has in-licensed a programme of
telomerase inhibitors from Cancer Research Technology Ltd, the
technology transfer arm of the charity Cancer Research UK.  This
programme was developed by Professor Stephen Neidle, working first at
the Institute of Cancer Research and more recently at the University
of London School of Pharmacy. Under the licensing agreement, Antisoma
has obtained rights to a number of existing molecules and an option
on further telomerase inhibitors generated by Professor Neidle's
group over the next three years.
Telomeres are the protective regions found at the ends of
chromosomes (the structures into which the genetic material, DNA, is
packaged in each cell of the human body).  In normal cells, telomeres
act as a 'life clock', shortening slightly each time the cell
divides. Once the telomeres fall below a critical length, the cell
undergoes the self-destruct process known as apoptosis or programmed
cell death. This is part of the natural process of cellular ageing
and removal of old cells to be replaced by new ones. Cancer cells
make an enzyme called telomerase that allows them to maintain their
telomeres at a length just sufficient to avoid entering the
self-destruct pathway. Telomerase thus enables cancer cells to divide
continually and indefinitely, a property fundamental to the
progression of the disease. By blocking the action of this enzyme,
telomerase inhibitors can prevent the maintenance of telomeres and
force cancer cells into apoptosis.
Glyn Edwards, CEO of Antisoma, said 'Telomerase inhibitors have
the potential for broad application against both solid and blood
cancers because the telomerase enzyme is important to all types of
cancer cell. This programme is an excellent addition to our
preclinical portfolio.'
Except for the historical information presented, certain matters
discussed in this statement are forward looking statements that are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from results, performance or
achievements expressed or implied by such statements. These risks and
uncertainties may be associated with product discovery and
development, including statements regarding the company's clinical
development programmes, the expected timing of clinical trials and
regulatory filings. Such statements are based on management's current
expectations, but actual results may differ materially.
About Antisoma
Based in London, UK, Antisoma is a biopharmaceutical company that
develops novel products for the treatment of cancer. The Company
fills its development pipeline by acquiring promising new product
candidates from internationally recognised academic or cancer
research institutions.  Its core activity is the preclinical
and clinical development of these drug candidates. Antisoma forms
partnerships with pharmaceutical companies to bring its products to
market.  In November 2002, Antisoma signed a ground-breaking
collaboration agreement with Roche to develop and commercialise
products from Antisoma's pipeline. Please visit www.antisoma.com for
further information.
About Cancer Research Technology Limited
Cancer Research Technology Limited (CRT) is a specialist
technology transfer company which aims to develop new discoveries in
cancer research for the benefit of cancer patients. CRT is wholly
owned by Cancer Research UK, the largest independent funder of cancer
research in the world. CRT works closely with leading international
cancer scientists and their institutes to protect intellectual
property arising from their research and to establish links with
commercial partners. CRT facilitates the discovery, development
and marketing of new cancer therapeutics, vaccines, diagnostics and
enabling technologies.
This information is provided by RNS
   The company news service from the London Stock Exchange

Contact:

Antisoma plc
Glyn Edwards,
Chief Executive Officer
Tel. +44/20 8799 8200

Financial Dynamics
Jonathan Birt
Tel. +44/20 7831 3113

Plus de actualités: Antisoma plc
Plus de actualités: Antisoma plc
  • 09.09.2003 – 08:38

    Antisoma Acquires Cytogen's Royalty Rights To R1549

    London, UK and Princeton, New Jersey USA (ots) - Antisoma plc (LSE: ASM; Nasdaq Europe: ASOM), a United Kingdom-based biopharmaceutical company, and Cytogen Corporation (Nasdaq: CYTO), a United States-based, product-driven, oncology-focused biopharmaceutical company, today announced that Antisoma has acquired certain royalty rights to Antisoma's lead product, R1549 (formerly Pemtumomab), from Cytogen. In connection ...

  • 22.08.2003 – 08:17

    Results Presented From As1403 Phase I Biodistribution Study

    London, UK plc (LSE:ASM, NASD-E:ASOM) (ots) - Antisoma announces that results from its phase I biodistribution study of AS1403 (formerly TheraFab) will be presented this weekend to the European Association of Nuclear Medicine meeting in Amsterdam by Dr Michael Garkavij, a leading investigator in the trial. AS1403 is a fragment of the monoclonal antibody HMFG1 linked to a radioactive isotope with cell-killing ...